The pharmaceutical industry tussles over biosimilars: federal and state decisions will have a big impact on pharmacists.
Unlike a generic drug, a "generic" biologic won't be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the "biosimilars" that will soon appear on the market.
Stephen
S
Barlas